Business
Directors' Dealings
Directors' Dealings.
About this update from 4basebio Plc
5 February 2024 4basebio plc (“4babsebio” or the "Company") Directors’ Dealings Cambridge, UK, 5 February 2024 - 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, thermostable nucleic acid delivery platform, announces that, further to its announcement of 2 February 2024, directors of the Company have sold shares in order to pay for options exercised as follows: Name Number of Shares Sold Sale price per share (p) Shareholding Following Sale Shareholding as a Percentage of Issued Share Capital Heikki Lanckriet 45,322 660p 1,418,994 11.09% David Roth 38,292 660p 457,708 3.58% The calculations above are based on an issued share capital of the Company of 12,796,208 ordinary shares. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310. For further enquiries, please contact: 4basebio PLC +44 (0)12 2396 7943 Heikki Lanckriet, CEO Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880 Jo Turner / Sandy Jamieson Cavendish Capital Markets Limited (Broker) +44 (0)20 7220 0500 Geoff Nash/Charlie Beeson Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated a. Name Dr Heikki Lanckriet David Roth 2 Reason for notification a. Position/Status CEO CFO b. Initial notification/ Amendment Initial Notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name 4basebio plc b. LEI 213800E2DX9EAIUNCB30 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a. Description of the financial instrument, type of instrument Identification Code Ordinary Shares ISIN: GB00BMCLYF79 b. Nature of the transaction Sale of Ordinary Shares Price(s) per share (p) Volume(s) 660p 660p 45,322 38,292 d. Aggregated information Volume Price 83,614 660 pence per share e. Date of the transaction 2/2/2024 f. Place of the transaction London Stock Exchange, AIM